ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY on Wednesday, September 10, 2025 at 2:00 p.m. ET. Management will be available for one-on-one meetings on Wednesd ...

KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA's biologics-based investigational therapies utilize KALA's proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potent ...

公司动态 - 公司管理层将于2025年6月5日下午1点25分在纽约举行的杰富瑞全球医疗保健会议上进行展示，并在当天接受一对一会议安排 [1] - 可访问公司网站“演示文稿”部分获取展示的网络直播和后续存档记录 [2] 公司概况 - 公司是临床阶段生物制药公司，致力于眼科罕见和严重疾病创新疗法的研发和商业化 [1][3] - 公司基于生物制剂的研究疗法采用专有的间充质干细胞分泌组（MSC - S）平台 [3] 产品信息 - 公司领先候选产品KPI - 012是一种人类MSC - S，含多种生物因子，可潜在纠正受损角膜愈合问题 [3] - KPI - 012目前正处于治疗持续性角膜上皮缺损（PCED）的临床开发阶段，已获美国食品药品监督管理局孤儿药和快速通道认定 [3] - 公司还针对KPI - 012治疗角膜缘干细胞缺乏症和其他威胁视力的罕见角膜疾病开展潜在开发，并已启动临床前研究评估其MSC - S平台对视网膜退行性疾病的潜在效用 [3] 投资者联系方式 - 投资者联系人为Taylor Steiner，邮箱为taylor.steiner@precisionaq.com，联系电话为212 - 362 - 1200 [4]